Regenerative medicine company Orthocell (ASX:OCC) has recorded its first sales revenue from its Remplir nerve repair product in the US.
Remplir is a collagen wrap used in nerve repair surgery to improve the regeneration of damaged nerves and patient outcomes.
The milestone follows the first surgical use of Remplir in late June and subsequent early surgical cases. The company said surgical cases conducted to date have been sourced from Orthocell’s network of nerve repair specialist distributors
Orthocell CEO and Managing Director, Paul Anderson, said, “Translating Remplir’s regulatory clearance in the US to first sales revenue in a little over three months is a testament to the hard work we’ve done with our US rollout plan. This covers everything from our key internal hires in sales, marketing and medical affairs, appointing specialist distributors, Australian manufacturing ramp up and working with our on-the-ground US logistics partner. I must stress these early-stage day surgery cases are an ideal starting point and represent the perfect strategic platform to build from. This approach is similar to the market access model we have successfully undertaken in Australia where early surgery cases build familiarity and knowledge, leading to widespread adoption and therefore revenue growth. We expect to follow a similar path in the US, albeit on a far larger scale. We are confident our efforts in the US are on track to drive growth in sales of Remplir during the second half of calendar 2025.”